ERBB2 and breast cancer: In patients with triple negative and human epidermal growth factor receptor 2 [HER2] -positive early breast cancer (EBC), not achieving pathological complete response (pCR), further systemic treatment is implemented in addition to neoadjuvant therapy (18).